Byron DeLaBarre, Ph.D.

Byron DeLaBarre, Ph.D.

Sr. Director of Structural Biology & Discovery Technology

EDUCATION
B.Sc., Applied Chemistry, University of Waterloo
M.Sc., Bioinorganic Chemistry, McMaster University
Ph.D., Biochemistry, McMaster University

PREVIOUS EXPERIENCE
Howard Hughes Medical Institute (Stanford)
Millennium Pharmaceuticals
Merrimack Pharmaceuticals
Agios Pharmaceuticals
Nimbus Therapeutics
plus over 30 companies as the Principal and Founder of "The Consulting Biochemist"

Byron’s Flare characteristics: A passion for finding new medical therapies. A maven of world-class science and technology to supercharge the efforts of this drug discovery team.

With over 20 years of experience in drug discovery research, Byron uses his broad scientific background to help define and solve the multiple challenges faced during the journey from target validation to approved therapeutic agent.

Byron has contributed to the creation and development of several molecules that are under clinical investigation. Two of these (TIBSOVO & IDHIFA), have received full approval as novel therapeutic agents for oncology with a third (MITIPIVAT) in late stage 3 trials for rare disease.

HOW DOES YOUR FLARE EXTEND INTO THE OUTSIDE WORLD?

I am driven by the judicious application of science and engineering to improve the quality of life around the planet.

WHAT SPARKED YOU TO JOIN FLARE?

The Flare team assembled to realize the promise and the challenge of modulating transcription factors to cure human disease.

managementall
 

This links to an external website.

Continue